Libigran is used across two primary therapeutic domains where supportive symptom management is appropriate. The medication may be part of symptomatic management in conditions characterized by periods of heightened symptoms, such as Erectile Dysfunction (ED) and Pulmonary Arterial Hypertension (PAH).

Support for Functional Male Sexual Health

Libigran is commonly used in situations involving certain distressing symptoms related to ED, a condition where the inability to achieve or maintain a functional erection creates noticeable physiological strain. This therapeutic area is applied across domains where additional symptomatic support is needed. The medication provides support that helps ease the overall symptom burden, assisting with maintaining functional stability when symptoms interfere with routine activities.

---

Management of Pulmonary Vascular Symptoms

The medication is also applied across domains where additional symptomatic support is needed for PAH, helping to manage symptom clusters such as shortness of breath and fatigue that interfere with daily functioning. Use in this context is considered relevant for easing the impact of symptoms and contributes to improved comfort during periods of heightened symptoms, helping to maintain a sense of stability when symptoms are more noticeable.

---

Quick Fact Block

Quick Fact: Support for Symptomatic Domains	Therapeutic Benefit
Functional Erection Impairment	Assists with maintaining functional stability.
Exertional Limitations (PAH)	Contributes to improved comfort and assists with maintaining functional stability.

Regulatory References

1. NIH MedlinePlus overview of Sildenafil uses

Libigran’s official eligibility profile is strictly defined by government regulatory bodies (e.g., FDA, EMA) based on patient population and pre-existing health status.

Contraindicated Populations (Must NOT Use)

Classification	Rule	Applicable Conditions
Absolute Exclusion	Patients receiving certain concurrent medications.	Organic nitrates (in any form) or the guanylate cyclase stimulator Riociguat are strictly prohibited.
Cardiovascular/Organ Status	Patients with high-risk clinical events or severe organ impairment.	Severe hepatic impairment, severe hypotension ( BP < 90/50 mmHg), or recent stroke or myocardial infarction.
Vision History	Patients with a history of a specific vision disorder.	Loss of vision in one eye due to non-arteritic anterior ischemic optic neuropathy (NAION).

Eligibility by Age and Condition

• Adults: The medicine is generally indicated for use in adult men (for ED) and adults (for PAH). No dose adjustment is strictly required for older adults ( 65 years) based on age alone.
• Pediatric Use: Libigran is not indicated for individuals under 18 years of age for the ED use. For the PAH indication, chronic use in children is generally not recommended.
• Organ Impairment: Use is permitted but requires special consideration or cautious initiation in patients with severe renal impairment or mild to moderate hepatic impairment, due to reduced drug clearance.
• Conditional Use: Caution is advised for patients with conditions predisposing to a prolonged erection (priapism, e.g., sickle cell anemia) or those with anatomical deformation of the penis.

Libigran Interactions with other medicines and products

Libigran, which contains Sildenafil, has documented interaction patterns based on its physiological effects and metabolic clearance. This information is derived exclusively from regulatory documents and relates to altered drug exposure and increased pharmacodynamic effects.

---

Formally Contraindicated Combinations

Co-administration of Libigran is strictly prohibited with the following classes of medicinal products, as mandated by regulatory authorities:

• Organic Nitrates and Nitric Oxide Donors: Including prescription medications (e.g., nitroglycerin, isosorbide dinitrate) and recreational products, due to a severe risk of potentiation of hypotensive (blood pressure-lowering) effects.
• Guanylate Cyclase (sGC) Stimulators: Such as riociguat, which is prohibited due to the potential for symptomatic hypotension.

---

Pharmacokinetic and Exposure Interactions

Sildenafil is primarily metabolized by the Cytochrome P450 3A4 (CYP3A4) enzyme. Substances that inhibit this enzyme can lead to significantly increased plasma concentrations (exposure) of Libigran. Strong inhibitors, including certain HIV protease inhibitors (e.g., ritonavir) and specific antifungal agents (e.g., ketoconazole, itraconazole), have been documented to raise Sildenafil exposure, requiring regulatory caution on dosage. Reduced clearance also occurs in patients with severe renal impairment or hepatic impairment, resulting in higher drug levels.

---

Pharmacodynamic and Other Interactions

Co-administration with alpha-blockers carries a documented risk of additive blood pressure-lowering effects. This effect is most likely to occur within four hours of Libigran dosing. Additionally, regulatory information notes that consuming a high-fat meal reduces the rate of absorption, which can delay the drug's activity.

Inhibition of the PDE5 Enzyme

Libigran acts as a selective competitive inhibitor of the enzyme Phosphodiesterase Type 5 (PDE5). This molecular action prevents the enzyme from performing its function, which is the hydrolysis of the cellular messenger cGMP to GMP.

---

Potentiation of the NO-cGMP Pathway

The drug's mechanism potentiates the body's natural Nitric Oxide (NO)-cGMP signaling pathway, which regulates local blood flow. By inhibiting the degradation of cGMP, the drug results in a sustained duration of cGMP activity following the initiation of the NO signal.

---

Modulation of Vascular Smooth Muscle Tone

The sustained increase in cGMP concentration triggers cascades that lead to the relaxation of vascular smooth muscle in specific tissues. This causes localized vasodilation (blood vessel widening) and the resulting increase in blood flow, which culminates in the physiological outcome of enhanced tissue engorgement.

Libigran (sildenafil) is administered according to specific instructions that differ based on the therapeutic indication: event-driven use for Erectile Dysfunction (ED) or chronic maintenance therapy for Pulmonary Arterial Hypertension (PAH). The product is available for oral administration as a film-coated tablet or, for PAH, as a reconstituted suspension. An intravenous (IV) bolus injection is an approved route for PAH patients who are temporarily unable to take the oral form.

Dosing Regimens and Frequency

Indication	Standard Adult Dosage	Maximum Frequency
Erectile Dysfunction (ED)	Initial dose of 50 mg, with a range of 25 mg to 100 mg.	Once per day (maximum).
Pulmonary Arterial Hypertension (PAH)	20 mg to 80 mg three times daily (TID) orally, or 10 mg TID via IV bolus injection.	Three times daily (TID).

Contextual Administration Rules

For ED, the tablet is taken as needed, typically 30 minutes to 4 hours before activity. The drug can be taken with or without food, although a high-fat meal may delay the onset of action, a key instruction for its event-driven use. A lower starting dose of 25 mg is considered for the ED indication in specific populations, including individuals aged 65 years and older or those with severe renal or hepatic impairment.

For PAH, doses are generally separated by approximately 4–8 hours. If a continuous PAH dose is missed, the next dose is taken as soon as possible to resume the regular schedule, with the instruction not to double the dose to compensate for the missed one.

Research evidence / Overview of studies for Libigran

The clinical evaluation of Libigran is summarized by research across two main areas, focusing on conditions marked by functional limitations. The available evidence, which includes randomized controlled trials and long-term observational studies, studies help show what has been observed so far, but research does not determine whether an individual will respond similarly.

Evidence for Use in Functional Erection Impairment (ED)

Research exploring how symptoms change over time in functional erection impairment has primarily involved short-term randomized controlled trials (RCTs) and supporting systematic reviews. These studies were applied in settings examining patient-reported experiences related to this condition. These trials research examined whether Sildenafil influences the ability to achieve and maintain an erection in adult males, monitoring changes in outcomes related to systemic or functional imbalance.

In these studies, researchers monitored patterns in patient-reported outcomes describing perceived discomfort and difficulty related to sexual activity. The research highlights changes measured during the study period, with findings describe patterns observed in the studies related to the reported quality and duration of erections in the observed populations. Data show patterns related to the observed populations, including in subgroups such as those with Diabetes Mellitus.

What remains uncertain is the full profile of long-term functional outcomes and the durability of the observed responses beyond the typically short follow-up durations of the controlled trials. Comparative evidence is lacking regarding other established treatment classes.

Evidence for Use in Pulmonary Arterial Hypertension (PAH)

Libigran was studied for pulmonary arterial hypertension, a condition where symptoms may vary in intensity. Research explored temporary physiological imbalance related to this condition through randomized, placebo-controlled trials and subsequent long-term extension studies.

Research examined outcomes reflecting daily functioning or activity level, such as the 6-Minute Walk Distance (6MWD). Findings describe patterns observed in the studies related to exercise capacity measures and the time between clinical events in the adult populations studied.

Long-Term Studies and Follow-Up Data

Research describes how symptoms evolved in the observed populations over defined time intervals. However, the long-term effects are not fully established regarding the sustained, durable response for all studied outcomes. Follow-up durations were limited for primary functional measures, which focused on the short-term changes observed during the initial study periods.

Evidence in Special Populations and Comorbidity Groups

Dedicated research was evaluated in specific populations, including adult males with ED and comorbid conditions. Furthermore, Libigran was studied for use in pediatric patients (children and adolescents) with PAH, a condition involving periods of heightened symptoms. Studies report how symptoms evolved in the observed pediatric populations over defined time intervals. However, long-term observation studies in the pediatric population was associated with specific concerns related to dose, and findings were mixed for some short-term functional measurements across different dose levels.

Research Gaps and Unanswered Questions

There is limited information for long-term outcomes regarding the functional effectiveness in many of the studied populations. Specifically, long-term effects are not fully established in the pediatric population due to research suggesting an association between higher dosages and specific outcomes in post-approval observation. The evidence quality varies across studies when analyzing specific subgroups.

Key Studies & References

1. Sildenafil: MedlinePlus Drug Information (NIH/NLM Patient Overview)

Common questions about Libigran (FAQ)

---

Q: Is Libigran used to treat any other health issues besides its main indication?

According to official regulatory documents, Libigran is approved and indicated only for the treatment of Erectile Dysfunction (ED) and Pulmonary Arterial Hypertension (PAH). These are the only two medical conditions for which the drug has been formally approved by major regulatory bodies.

---

Q: Does Libigran affect a person's sexual desire or libido?

The medicine's mechanism of action works by regulating blood flow in specific tissues. Official information clarifies that Libigran does not cause or increase sexual arousal or desire by itself. Sexual arousal is still required to initiate the intended physiological effect.

---

Q: Does drinking alcohol affect the safety or function of Libigran?

Drinking alcohol while taking Libigran may increase the risk of certain side effects, such as headache, flushing, or dizziness. Official prescribing information indicates that consuming large amounts of alcohol may also make it more difficult to achieve an erection, potentially reducing the medicine's effectiveness.

---

Q: What common over-the-counter medicines or supplements are known to interact with Libigran?

Regulatory documents advise against consuming grapefruit juice when taking Libigran for the PAH indication, as it may affect how the medicine works. Additionally, other products that inhibit the CYP3A4 enzyme (a specific liver enzyme) may increase the body's exposure to Libigran.

---

Q: Is a headache a frequently reported side effect when using Libigran?

Yes, headache is listed in official documentation as one of the most common side effects reported by patients who use the medicine.

---

Q: Can Libigran cause a temporary change in vision or affect a person's eyesight?

Official information reports that Libigran can cause transient (temporary) effects such as changes in color vision (e.g., a blue tint), blurred vision, or increased sensitivity to light. Sudden vision loss has also been reported as a rare, serious side effect.

---

Q: What steps are described in official documents if an erection lasts longer than four hours?

If an erection lasts longer than four hours, official documents include a warning that immediate medical attention is required. This condition is known as priapism and can cause permanent tissue damage if not treated promptly.

---

Q: Are there any known serious side effects linked to long-term use of Libigran?

Studies have examined the long-term safety profile of Libigran for the ED indication over several years. Evidence indicates the medicine has generally been well-tolerated, with no new safety risks or loss of effectiveness identified over time.

---

Q: Can people who have been diagnosed with diabetes use Libigran?

Official information notes that sildenafil (the active ingredient in Libigran) has been used as a standard treatment for erectile dysfunction, including in males who have diabetes mellitus.

---

Q: Have clinical trials studied the effects of Libigran in women?

Libigran for the ED indication is not approved for use in women. However, the active ingredient, sildenafil, is approved and indicated for use in adult women and children for the treatment of Pulmonary Arterial Hypertension (PAH).

---

Q: Does the drug cause spontaneous erections without any sexual arousal?

No. The drug's mechanism requires a natural signal from the body (sexual arousal) to begin working. Official information states that Libigran does not cause spontaneous erections without stimulation.

---

Q: Is Libigran suitable for people with severe kidney or liver problems?

The drug's clearance (how the body processes it) is reduced in patients with severe kidney or liver impairment. Official documents note that the medicine has not been well-studied in the most severe hepatic impairment for the ED indication. For these and other situations, the product label describes the need for dose adjustment or careful monitoring.

---

Q: Is there an age restriction for the use of Libigran?

Libigran for the ED indication is generally intended for men aged 18 and older. However, the active ingredient is also approved for the treatment of Pulmonary Arterial Hypertension (PAH) in both adults and pediatric patients aged 1 year and older.

---

Q: What is the overall research evidence that supports the use of Libigran?

The safety and effectiveness of Libigran are established through comprehensive clinical trial programs. Official documentation references extensive patient exposure across more than 120 manufacturer-sponsored trials.

---

Q: Where can a patient find reliable, official summaries of the research done on Libigran?

Official summaries and prescribing information for Libigran are published on government health websites. This includes the National Institutes of Health's MedlinePlus and the FDA's DailyMed database.

---

Q: What are the known health risks associated with buying unauthorized or counterfeit versions of Libigran?

Regulatory bodies have issued public health warnings against counterfeit versions of Libigran, which are illegal and can pose serious health risks due to unknown or potentially harmful ingredients. Regulatory warnings highlight the dangers of using unauthorized medicines.

---

Q: Is the use of Libigran affected by physical deformity of the penis?

Official warnings advise that Libigran should be used with caution in patients who have an anatomical deformation of the penis, such as angulation or Peyronie's disease.

---

Q: Is taking Libigran considered a safe option for someone with uncontrolled high blood pressure?

Official contraindications include having uncontrolled high blood pressure (typically defined as above 170/110 mmHg). A person with this condition may be overly sensitive to the drug’s blood pressure-lowering effects.

---

Q: Does Libigran work differently for people with conditions like sickle cell anemia?

Regulatory documents advise that Libigran should be used with caution in people with conditions that may predispose them to a prolonged erection, such as sickle cell anemia or multiple myeloma.

---

Q: What is the documented risk of feeling dizzy or faint after taking Libigran?

Dizziness is listed in official documentation as a common side effect of Libigran. This effect is related to its property of widening blood vessels.

---

Q: Does the drug affect a person's ability to drive or operate machinery?

While no formal studies on the effects on the ability to drive or use machinery have been performed, official documents note that patients may experience side effects, such as dizziness or vision changes. These potential effects should be considered before driving or operating machinery.

---

Official Storage and Disposal Requirements

Regulatory documentation defines strict conditions for storing Libigran (Sildenafil citrate) to maintain its stability and effectiveness, alongside mandatory rules for its safe disposal.

Requirement	Official Instruction
Storage Temperature	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with excursions permitted to 30 C.
Environmental Protection	Must be protected from moisture and must not be frozen. Avoid storing in high-humidity areas, such as the bathroom.
Container Requirements	Keep the medicine in its original container with the lid tightly closed to maintain protection from moisture.
Child Safety	It is mandatory to keep the product out of the sight and reach of children and away from pets.
Disposal	Dispose of unused or expired medicine according to local regulations. Utilize a drug take-back program when available.
Environmental Rule	Do not flush the tablets down the toilet or throw them into wastewater systems, as they are not on the list of medicines required to be flushed.